"uuid:ID","label","instanceType","rationale","description","id","name"
"48eb2845-e69c-4c7d-acee-ec2352a82f20","","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","StudyDesign_1","Study Design 1"
